Paul Hastings LLP advised Orchestra BioMed on the deal.Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the closing of a $110 million…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
